USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
FIRSTSTRING RESEARCH, LLC
Address:
300 West Coleman Blvd.
Mt. Pleasant, SC 29464-
Phone:
N/A
URL:
N/A
EIN:
187077927
DUNS:
602545654
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $522,752.00 3
SBIR Phase II $641,088.00 1
STTR Phase I $152,255.00 1

Award List:

Restoration of Skin Structure and Function Post-Wounding

Award Year / Program / Phase:
2006 / STTR / Phase I
Award Amount:
$152,255.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEDICAL UNIVERSITY OF SOUTH CAROLINA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The wound repair process in skin is initiated immediately after an injury and induces a cascade of events including inflammation, proliferation, and scar production/tissue remodeling. One of the common complications of wound healing is excessive scarring, leading… More

Evaluation of a novel connexin-based peptide for the treatment of diabetic wounds

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$141,189.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): According to the American Diabetes Association, there are more than 16 million people in the United States with known diabetes. Diabetic patients commonly demonstrate impaired wound healing. Approximately 20 percent of patients with diabetes will develop foot… More

Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$641,088.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): According to the American Diabetes Association, there are more than 16 million people in the United States with known diabetes. Diabetic patients commonly demonstrate impaired wound healing. Approximately 20 percent of patients with diabetes will develop foot… More

SBIR Phase I: Novel Connexin-Based Peptide for the Treatment of Age-Related Macular Degeneration

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$148,803.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project is a feasibility assessment of the ocular delivery of a synthetic peptide, ACT1, for the treatment of Age-Related Macular Degeneration (AMD). AMD is a retinal disease in patients who progressively lose their central vision through… More

Development of a novel connexin-based peptide for the treatment of corneal injury

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$232,760.00
Agency:
HHS
Principal Investigator:
Gautam S. Ghatnekar – 843-860-8785
Abstract:
DESCRIPTION (provided by applicant): According to the World Health Organization, at least 171 million people worldwide are living with diabetes and this figure is likely to more than double by the year 2030. Because of its chronic nature, the severity of its complications and the means required to… More